A recent study demonstrated that Erythropoiesis-stimulating agents, a widely used drug to treat anemia, may have a negative impact on the survival of myeloma patients.
A recent study demonstrated that Erythropoiesis-stimulating agents, a widely used drug to treat anemia, may have a negative impact on the survival of myeloma patients.